Platinum-resistant Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Platinum-resistant Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-24Clinical Trial Results: Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer [Phase 2]
Phase 2 trial results for elenagen plasmid in combination with gemcitabine show efficacy in platinum-resistant ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
Phase 3 trial evaluating Rina-S vs investigator's choice in platinum-resistant ovarian cancer; study status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
Phase 3 trial evaluating Rina-S versus investigator's choice in platinum-resistant ovarian cancer; status active_not_recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
Phase 3 trial evaluating Rina-S versus investigator's choice in platinum-resistant ovarian cancer; status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors [Phase 1]
Context Therapeutics reports an ongoing Phase 1 study of CTIM-76 in platinum-resistant ovarian cancer and other advanced solid tumors, with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]
This clinical trial update reports the completion of a Phase 1/2 study evaluating the combination of Azenosertib (ZN-c3) and Niraparib in pl…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers [Phase 1]
Phase 1b study evaluating SL-172154 in combination with other agents in platinum-resistant ovarian, fallopian tube, and primary peritoneal c…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian [Phase 2]
A phase 2 trial evaluating afuresertib in combination with paclitaxel for platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) [Phase 3]
A Phase 3 study assessing nemvaleukin alfa in combination with pembrolizumab for platinum-resistant ovarian cancer has been terminated. Resu…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer [Phase 2, Phase 3]
A Phase 2/3 trial evaluating PCC + Bevacizumab + CA4P vs PCC + Bevacizumab + Placebo for platinum-resistant ovarian cancer was terminated, w…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1]
A Phase 1 trial evaluates the combination of mirvetuximab soravtansine and rucaparib camsylate in patients with recurrent gynecologic cancer…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) [Phase 2]
Phase 2 study MK-2140-002 evaluating Zilovertamab vedotin (VLS-101) in solid tumors including triple-negative breast cancer and non-small-ce…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1]
XMT-1536, an investigational NaPi2b-targeting agent from Mersana Therapeutics, completed a first-in-human Phase 1 dose-escalation study in c…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial of DSP-7888 Dosing Emulsion in combination with immune checkpoint inhibitors in adults with advanced solid tumors was termin…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1, Phase 2]
First-in-human study of XMT-1536 in cancers likely to express NaPi2b, including platinum-resistant ovarian cancer and metastatic non-small c…
-
CLINICAL_TRIALS trial_result · 2023-10-30Clinical Trial Update: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer [Phase 3]
Phase 3 trial of Batiraxcept (AVB-S6-500) plus paclitaxel in platinum-resistant recurrent ovarian cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating plasmid Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer; status and results are not …
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) [Phase 3]
Phase 3 trial of VB-111 plus paclitaxel versus paclitaxel alone in recurrent platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating albumin-bound paclitaxel in combination with bevacizumab for platinum-resistant recurrent ovarian cancer…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer [Phase 3]
Phase 3 trial comparing TQB2450 with Anlotinib capsules versus Paclitaxel weekly for relapsed platinum-resistant ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer [Phase 2]
Phase 2 clinical trial evaluating dual therapy with Anlotinib and Niraparib for platinum-resistant recurrent ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating cediranib plus olaparib in recurrent platinum-resistant ovarian cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer [Phase 1, Phase 2]
Phase I/II trial of VB-111 with paclitaxel for platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-04-04Clinical Trial Update: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer [Phase 1, Phase 2]
Phase 1/2 trial of CRS-207 with epacadostat in platinum-resistant ovarian, fallopian, or peritoneal cancer has been terminated; results post…
-
CLINICAL_TRIALS trial_result · 2019-03-19Clinical Trial Update: A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial investigating ABT-263 as a single agent in women with platinum-resistant or refractory recurrent ovarian cancer has completed.